(SYRE) Spyre Therapeutics - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 6.454m USD | Total Return: 391.4% in 12m
Avg Turnover: 74.5M
Warnings
Share dilution 474.2% YoY
Altman Z'' -15.00 < 1.0 - financial distress zone
Tailwinds
Supp Ema20, Leader, Tailwind, Pullback 52w
Spyre Therapeutics (NASDAQ: SYRE) is a clinical-stage biotechnology firm specializing in the development of targeted therapies for inflammatory bowel disease (IBD) and rheumatic conditions. The companys pipeline focuses on humanized monoclonal antibodies, including SPY001, which targets the a4ß7 integrin, and candidates targeting TL1A and IL-23. Beyond monotherapies, Spyre is advancing combination treatments, such as SPY120 and SPY130, to address complex immune-mediated pathways.
The biotechnology sector often utilizes monoclonal antibodies to achieve high specificity in autoimmune treatments, reducing off-target effects compared to traditional systemic immunosuppressants. Spyre operates under a high-risk, high-reward research and development model, where valuation is primarily driven by clinical trial milestones and the pursuit of regulatory approvals for novel biologic drug candidates.
Investors looking for deeper fundamental insights into this sector may find ValueRay to be a useful resource for further analysis.
- Clinical trial results for lead candidate SPY001 dictate near-term market valuation
- Development progress of anti-TL1A and IL-23 candidates influences long-term competitive positioning
- Strategic combination therapies create differentiation in the crowded inflammatory bowel disease market
- Cash runway and future equity financing rounds impact shareholder dilution and liquidity
- Regulatory approvals for ulcerative colitis and Crohns disease drive path to commercialization
| Net Income: -179.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.24 > 0.02 and ΔFCF/TA 5.49 > 1.0 |
| NWC/Revenue: 750.1% < 20% (prev 56.3k%; Δ -55.6k% < -1%) |
| CFO/TA -0.24 > 3% & CFO -185.8m > Net Income -179.4m |
| Net Debt/EBITDA: error (cannot be calculated) |
| Current Ratio: 8.97 > 1.5 & < 3 |
| Outstanding Shares: last quarter (346.0m) vs 12m ago 474.2% < -2% |
| Gross Margin: -89.68% > 18% (prev -0.09%; Δ -8.96k% > 0.5%) |
| Asset Turnover: 13.57% > 50% (prev 0.16%; Δ 13.41% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.89 (Total Current Assets 764.0m - Total Current Liabilities 85.2m) / Total Assets 764.0m |
| B: -1.57 (Retained Earnings -1.20b / Total Assets 764.0m) |
| C: -0.35 (EBIT TTM -231.6m / Avg Total Assets 666.9m) |
| D: -12.86 (Book Value of Equity -1.20b / Total Liabilities 93.1m) |
| Altman-Z'' = -15.11 = D |
As of May 24, 2026, the stock is trading at USD 74.32 with a total of 730,461 shares traded.
Over the past week, the price has changed by -1.16%,
over one month by +1.44%,
over three months by +67.61% and
over the past year by +391.37%.
Spyre Therapeutics has received a consensus analysts rating of 4.82. Therefore, it is recommended to buy SYRE.
- StrongBuy: 10
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 95.2 | 28.1% |
P/B = 12.5205
Revenue TTM = 90.5m USD
EBIT TTM = -231.6m USD
EBITDA TTM = -221.6m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 5.71b USD (6.45b + (null Debt) - CCE 741.5m)
Interest Coverage Ratio = unknown (Ebit TTM -231.6m / Interest Expense TTM 0.0)
EV/FCF = -30.75x (Enterprise Value 5.71b / FCF TTM -185.8m)
FCF Yield = -3.25% (FCF TTM -185.8m / Enterprise Value 5.71b)
FCF Margin = -205.3% (FCF TTM -185.8m / Revenue TTM 90.5m)
Net Margin = -198.3% (Net Income TTM -179.4m / Revenue TTM 90.5m)
Gross Margin = -89.68% ((Revenue TTM 90.5m - Cost of Revenue TTM 171.7m) / Revenue TTM)
Gross Margin QoQ = none% (prev 50.0%)
Tobins Q-Ratio = 7.48 (Enterprise Value 5.71b / Total Assets 764.0m)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = -183.0m (EBIT -231.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.97 (Total Current Assets 764.0m / Total Current Liabilities 85.2m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA -221.6m)
Debt / FCF = unknown (Net Debt none / FCF TTM -185.8m)
Total Stockholder Equity = 574.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -26.91% (Net Income -179.4m / Total Assets 764.0m)
RoE = -10.13% (Net Income TTM -179.4m / Total Stockholder Equity 1.77b)
RoCE = -34.12% (EBIT -231.6m / Capital Employed (Total Assets 764.0m - Current Liab 85.2m))
RoIC = -29.51% (negative operating profit) (NOPAT -183.0m / Invested Capital 620.2m)
WACC = 12.39% (E(6.45b)/V(6.45b) * Re(12.39%) + (debt-free company))
Discount Rate = 12.39% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 89.89 | Cagr: 242.4%
[DCF] Fair Price = unknown (Cash Flow -185.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.29 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.71 | Chg30d=-2.01% | Revisions=-14% | Analysts=13
EPS next Quarter (2026-09-30): EPS=-0.69 | Chg30d=-2.70% | Revisions=+14% | Analysts=13
EPS current Year (2026-12-31): EPS=-2.83 | Chg30d=-0.14% | Revisions=-20% | GrowthEPS=-43.0% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-3.01 | Chg30d=+0.40% | Revisions=-25% | GrowthEPS=-6.3% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -25%